Kornimate/medical-research-clean huggingface dataset:
functional interest of non invasive brain stimulation during physiotherapy at a subacute phase post stroke (anodal protocol): restim

Conditions: Stroke

Summary: previous research that utilises single sessions of transcranial direct current stimulation (tdcs) have demonstrated functional improvements. however these improvements are usually short-lived, lasting less than one hour before the patient's performance returns to baseline. in these studies, tdcs is typically applied with the goal of adaptively enhancing functional activation of pathologically under-active tissue or suppressing pathologically over-active tissue. interestingly, a small body of evidence is now emerging to indicate that tdcs can improve learning/memory functions in healthy controls. the goal of this study is to test if the application of tdcs could enhance learning and/or memory for physiotherapy rehabilitation, which may in turn lead to correspondingly greater motor improvement. patients at a subacute stage (1 to 6 month post stroke) will attend for 10 consecutive daily sessions of tdcs. this research has important implications; previous studies suggest that such an approach has the potential to facilitate physical rehabilitation post-stroke and establish tdcs as a clinically viable rehabilitative tool. recovery of motor skills may take many months to acquire and therefore strategies that have the potential to enhance acquisition of skill are of practical and scientific interest.


Eligibility criteria:
inclusion criteria: * all subjects must be between the ages of 18-90 and must not be pregnant. * patients volunteer to participate in the study, with a written informed consent signed * affiliation to a national health insurance program * first-time clinical ischemic or hemorrhagic cerebrovascular accident - evidenced by a radiological (or physician's) report * contralesional motor deficit * lesion sparing primary motor cortex * stroke onset \>1 month and \<6 months prior to study enrollment exclusion criteria: * coexistent major neurological or psychiatric disease as to decrease number of confounders * history of epilepsy before stroke (or episodes of seizures within the last six months) * any substantial decrease in alertness, language reception, or attention that might interfere with understanding instructions for motor testing * subjects with global aphasia and deficits of comprehension * excessive pain in any joint of the paretic extremity (vas\>4) * contraindications to tdcs : metal in the head, implanted brain medical devices * coexistent major neurological or psychiatric disease as to decrease number of confounders * a history of significant alcohol or drug abuse in the prior 6 months * anyone who is currently taking or who has taken anti-malarial treatment in the last 72 hours * subjects may not have already received constraint induced motor therapy and/or tdcs treatment for stroke * pregnancy

Keywords: stroke transcranial direct current stimulation (tdcs) motor function
in vitro maturation induction of oocytes from a woman with syndrome of repeated oocyte maturation failure in vitro

Conditions: Oocyte Maturation Failure

Summary: donated oocytes is from a patient with repeated oocyte maturation failure in ivf cycles. cytoplasm of matured metaphase ii oocyte and active mpf were injected into the donated oocytes.

the study reported a woman with syndrome of repeated oocyte maturation failure where there is repeated production of immature oocytes.she underwent two ivf cycles in other hospital. all oocytes obtained were immature and the treatment were stopped.she underwent her third try in our hospital. the couple gave their informed consent: icsi will be performed if maturation occurred, otherwise, the treatment would be stopped and the oocytes would be donated for study if the oocytes were not matured after 24 hours of culture. after ovarian hyperstimulation,14 oocytes were obtained. none of them was matured. the cycle was canceled and the oocytes were donated for study.to induce the immature oocytes in vitro, oocytes were 1)cultured in follicular fluid containing matured metaphase ii oocyte; 2) performed intracytoplasmic sperm injection (icsi) to induce intracellular ca2+\]i oscillations; 3)injected with active maturation promoting factor (mpf), 4)injected with cytoplasm of matured metaphase ii oocyte.

Eligibility criteria:
inclusion criteria: clinical diagnosis of syndrome of repeated oocyte maturation exclusion criteria: patients with matured oocytes in ivf cycles

Keywords: oocyte maturation failure maturation induction in vitro
esgvs: sclerotherapy with lauromacrogol

Conditions: Venous Insufficiency; Saphenous Vein

Summary: to evaluate the efficacy and the tolerance of echoguided sclerotherapy using lauromacrogol 400 foam for the treatment of great saphenous vein (gsv) insufficiency. a comparative study of 3% versus 1% lauromacrogol 400 foam.

a multicenter randomized double blind study to evaluate the efficacy and the tolerance of echoguided sclerotherapy using 3% versus 1% lauromacrogol 400 foam in the treatment of great saphenous vein (gsv) insufficiency. one hundred fifty eligible patients will be recruited during 6 months from 9 study centers with a follow up period of 3 years and 7 visits at day 8, 6 weeks, 3 months, 6 months, 1,2 ,and 3 years. after randomization, the patients will be treated by echoguided sclerotherapy with 1% or 3% lauromacrogol 400 foam (ratio 1:1). monitoring is performed by doppler at 8 days, 6 weeks, 6 months , 1,2 ,and 3 years. effectiveness of sclerotherapy is determined at 6 weeks, 3 months and 6 months. a additional injection of 4 ml of foam can be performed if needed. severity clinical score and quality-of-life questionnaire are performed at 6 months ,1 ,2, and 3 years. the absence of obliteration with a reflux of crural great saphenous vein at 6 months will be a criterion of therapeutic failure. the therapeutic success or failure criteria are evaluated by a non investigator angiologist for 5 patients randomized from each investigational site at 1, 2 and 3 years.

Eligibility criteria:
inclusion criteria: * 25 - 75 years * hawaii ceap classification : c2-5 ep, as2-3 pr * clinical varicose veins c2, edema c3, skin changes c4, healed ulcer c5 * etiology ep primary gsv insufficiency * as2-3: ostial and or crural truncular gvs incompetence * maximal inferior diameter of the leg gsv (patient in decubitus) between 4 and 8mm * pr: reflux by echo doppler in orthostatism \> 1 second * information consent form signed by the investigator and the patient. exclusion criteria: * deep venous reflux (ceap: ad) * short saphenous vein or non saphenous network insufficiency (ceap: a4-5) * clinical class: c1 or c6 * recurrent gsv varicose veins after stripping * thrombophilia or antecedent of deep vein thrombosis * psychiatric disorders * known allergy to lauromacrogol or to one of its component * arteriopathy. (ips \< 0.8) * post-thrombotic disease * chronic hepatoma * renal insufficiency (creatinine \> 150 micromol/l)

Keywords: lauromacrogol sclerotherapy
conversion of seddon iii nerve injury to seddon i/ii nerve injury

Conditions: Injury of Other Nerves at Wrist and Hand Level of Unspecified Arm, Initial Encounter

Summary: this study will evaluate the safety and efficacy of peg 3350 for use in nerve repair.

to demonstrate more rapid and increased return of function by peg-fusion compared to the best current nerve repair techniques. neurorrhaphy is not new, being performed now for over 150 years much research has been performed. peg-axon fusion on the other hand is relatively new in mammals. success has already been obtained by two institutions in the rat sciatic nerve transections, demonstrating rapid return of behavioral function4. these however are very controlled injuries and unclear how well these will translate into human studies. for this reason 3 separate clinical studies in increasing order of complexity are proposed. the first study proposed will be peg fusion in digital nerve lacerations. two goals will be demonstrated; improved innervation density and improved innervation threshold compared to traditional repair, and complication rate similar or less than traditional repair. this will demonstrate the safety and efficacy of the procedure.

Eligibility criteria:
* isolated nerve transections of the digits, forearm, wrist, and palm will be included. * class iii nerve injury (sunderland's 4th or 5th degree injury) * nerve injuries that can be prepared using minimal or acceptable tension (according to surgeon discretion). * pregnant and breastfeeding women cannot participate because of possible unknown and unpredictable risks to the unborn child. * injuries beyond 24 hours will be excluded
effect of danazol on endometrial αvβ3 integrin expression in patients with unexplained recurrent implantation failure

Conditions: Unexplained Infertility

Summary: this study investigates the presence of a possible link between treatment with danazol and expression of endometrial αvβ3 integrin which might allow tailoring of danazol treatment to the subset of repeated ivf/et failure that might benefit most from it. 38 eligible ovulatory women were recruited aged 20 - 38 years with unexplained recurrent implantation failure (rif). timed suction endometrial biopsy was obtained from participants during the implantation window of the pretreatment cycle, followed by immunohistochemical staining for endometrial αvβ3 integrin expression, scored using h-score. participants were treated with danazol (danol® 200mg capsules, sanofi, guildford, uk) in daily dosage of 400 mg for 12 weeks. post-treatment suction endometrial biopsy was obtained during the implantation window following the first ovulation after danazol treatment and endometrial αvβ3 integrin expression was compared to the pretreatment cycle.


Eligibility criteria:
inclusion criteria: * age: 20-38 yrs * unexplained recurrent implantation failure (rif), defined as failure to achieve an intrauterine gestational sac recognized by ultrasonography after transfer of at least four good-quality embryos (defined as those with four or five blastomeres on day 2, seven or more cells on day 3, ≤ 20% anucleated fragments and absence multinucleated blastomeres) in a minimum of three fresh or frozen ivf cycles after exclusion of other causes of rif (as depicted by normal transvaginal ultrasonography, hysteroscopy, hysterosalpingography, laparoscopic findings, male and female karyotypic examination, endocrinological profile during ovarian stimulation and negative anti-cardiolipin antibody igm/igg, lupus anticoagulant, thrombophilia screening (including protein c, protein s, anti thrombin iii and factor v leiden) and normal male semen analysis as depicted by 2010 who criteria for semen analysis and sperm dna fragmentation testing). exclusion criteria: * anovulation * contraindications to treatment with danazol (including chronic liver disease, congestive heart failure, dyslipidemia or history/current thrombo-embolic disease) * medical comorbidities (e.g. autoimmune disorders, diabetes mellitus, etc) * patients who underwent induction of ovulation / received hormonal treatment during the previous three months
predictors and outcomes of time to hemostasis after cardiac catheterization

Conditions: Acute Coronary Syndrome

Summary: this study aims to: 1. assess the incidence of hemostasis failure after manual compression of trans-femoral arterial sheath post percutaneous coronary intervention. 2. assess the predictors of time to hemostasis achieved by manual compression for trans-femoral arterial sheath post percutaneous coronary intervention. 3. assess the association between time to hemostasis and the incidence of vascular access complications after manual compression for trans-femoral arterial sheath removal post percutaneous coronary intervention. 4. assess the association between failed hemostasis and the incidence of vascular access complications after manual compression for trans-femoral arterial sheath removal post percutaneous coronary intervention.

nurses and medical professionals have a vital role in detecting, preventing, and managing complications at the earliest possible stage. they should assess patients for high risk of complications, and plan management strategies to decrease those complications. in many acute and critical care settings, removing femoral sheaths and handling related complications after percutaneous coronary intervention. are primarily the responsibilities of nurses. therefore, after catheterization procedures, assessing the predictors of required time to achieve optimal hemostasis at the time of trans-femoral arterial sheath removal is essential as one of the final modifiable measures to prevent access site complications. this study will be done in 6 cardiac catheterization units representing governmental and private hospitals. a sample size of 266 patients will be recruited for the study. data will be analyzed by univariate and multivariate analysis.

Eligibility criteria:
inclusion criteria: * patients who planned for elective or primary percutaneous coronary intervention with femoral access, and * agreed to participate in the study exclusion criteria: * patients who had trans-femoral catheterization procedure within a 1-month duration * patients with a known history of coagulation disorders, * patients with sheath removed at the laboratory, and * patients who experience post - catheterization life-threatening events rather than vascular access complications
al amyloidosis and anti-cd38-daratunumab

Conditions: Amyloidosis

Summary: al amyloidosis and anti-cd38

al amyloidosis is a systemic disorder characterized by progressive multiorgan failure and premature death. while autologous stem cell transplantation (asct) is considered the standard therapy, eligibility is limited, and excludes a substantial proportion of patients. recent guidelines recommend daratumumab-based regimens for these patients, but, particularly for cases with severe renal involvement, optimal treatment remains a challenge. this study explore the efficacy of daratumumab monotherapy in patients with histologically proven severe renal involvement who are ineligible for asct

Eligibility criteria:
inclusion criteria: * patients affected by al amyloidosis * patients who were ineligible for high dose therapy and bone marrow transplantation due to age and/or frailty score. exclusion criteria: - diagnosis of al amyloidosis not biospy proven
ceus improves the diagnostic performance of srss of thyroid carcinoma

Conditions: Thyroid Nodule; Thyroid Carcinoma

Summary: contrast-enhanced ultrasound (ceus) can sensitively show the blood perfusion characteristics of thyroid nodules, which is a useful supplement to gray-scale ultrasound. however, there is no standard combined diagnostic method of gray-scale ultrasound and ceus. therefore, the aim of this study was to compare the diagnostic performance of the integrated scoring method and the up-and-down scoring method. this study was a multicenter retrospective clinical study and followed the standards for reporting of diagnostic accuracy studies (version 2015). inclusion criteria: 1) participants with at least one thyroid nodule larger than 5 mm confirmed by conventional ultrasound; 2) participants underwent gray-scale ultrasound, contrast-enhanced ultrasound and fine needle aspiration biopsy of the thyroid nodule successively; 3) participants have a final diagnosis of benign or malignant. exclusion criteria included: 1) participants with cytologic findings of bethesda i, iii, or iv without definitive benign or malignant pathologic findings; 2) participants with a history of thyroid fine needle aspiration, ablation or surgery; 3) participants with low quality ultrasound images (e.g., severe artifacts or low image resolution). according to the american college of radiology thyroid imaging reporting and data system, only one thyroid nodule with the highest point was included in each participant. a total of 600 participants from january 2018 to december 2022 were consecutively included in sun yat-sen memorial hospital of sun yat-sen university to form a training set (average age 48 years; range 24-81 years old). a total of 200 subjects with thyroid nodules from january 2022 to december 2022 were consecutively included to form an external validation set in houjie hospital of dongguan city, guangdong province (mean age 46 years; range 30-74 years). the malignant risk of enrolled thyroid nodules and the necessity of biopsy were evaluated by integrated scoring method and up-and-down scoring method, respectively. the diagnostic performance and unnecessary biopsy rate of the above two methods were calculated and compared.


Eligibility criteria:
inclusion criteria: * participants with thyroid nodules with a solid component ≥5 mm confirmed by conventional ultrasound; * participants who underwent conventional ultrasound, contrast-enhanced ultrasound, and fine-needle aspiration biopsy; * participants with a final benign or malignant pathological results. exclusion criteria: * participants with cytopathology of bethesda i, iii, or iv and without final benign or malignant pathology； * participants with a history of thyroid ablation or surgery; * participants with low-quality ultrasound images.

Keywords: thyroid nodule contrast media gray-scale ultrasound diagnosis biopsy
predicting adenomatous polyps in the colon using images of a human tongue

Conditions: Colorectal Neoplasms; Gastrointestinal Microbiome

Summary: this is a prospective, multicenter, single-arm clinical investigation designed to evaluate the accuracy of the gixam™ system in identifying subjects with colorectal adenomas compared to optical colonoscopy. subjects arriving for a standard of care colonoscopy at the investigation site will be offered to participate in the study. following an informed consent process, images of the subjects' tongue will be obtained with the gixam™ system and a prediction score will be generated by the gixam™ ai model. subjects will thereafter proceed to their soc colonoscopy, and the gixam™ score will be compare with colonoscopy findings to evaluate its performance.


Eligibility criteria:
inclusion criteria: 1. males or females 2. age: 18-75 years, inclusive 3. scheduled for colonoscopy procedure at investigation site subject to one of the below criteria: 1. screening - defined as first colonoscopy or consecutive colonoscopy without previous findings, previous colonoscopy performed at least 10 years ago (- 1 year); 2. patient with finding of colorectal adenoma or sessile serrated polyp in previous colonoscopy (must be documented in patient's medical history). 4. able to comprehend and provide informed consent. exclusion criteria: 1. subject who is not a suitable candidate for a colonoscopy 2. lynch or familial adenomatous polyposis (fap) inherited syndromes 3. current or previous inflammatory bowel disease (ibd - crohn's, ulcerative colitis) of significant duration 4. patients with a disability to extend their tongue. 5. patients with tongue piercings.

Keywords: artificial intelligence
study of wa-ng telescope prosthesis in patients with end-stage age-related macular degeneration

Conditions: Age Related Macular Degeneration

Summary: this is a pilot study to evaluate the safety of the model wa-ng telescope prosthesis in patients with bilateral moderate to profound central vision impairment due to end-stage age-related macular degeneration.

patients will be screened for eligibility and informed consent will be obtained from those who meet screening criteria and are interested in participating in the study. eligible patients will be examined preoperatively to obtain a medical history and to establish a baseline for ocular condition. baseline measurements will include successful use of an external telescope. postoperatively, patients will undergo ophthalmic evaluation at regular intervals as specified in this protocol and will be required to return for 6 to 10 additional visits for vision training with a low vision specialist.

Eligibility criteria:
inclusion criteria: bi-lateral, stable, moderate to profound (20/80 to 20/800) central vision impairment due to bilateral scotoma associated with end-stage macular degeneration, defined as retinal finds of bilateral, geographic atrophy or disciform scar with foveal involvment. phakic in the operative eye. must achieve a 5 letter improved with external telescope simulator. exclusion criteria: evidence of active cnv or any ophthalmic pathology that compromises peripheral vision of fellow eye or predisposes eye rubbing. previous intraocular of corneal surgery of any kind in operative eye. retinal disease, optic nerve disease, diabetic retinopathy, retinal tears, or any introcular tumor or medical or ophthalmic condition that in the opinion of the investigator renders the subject unsuitable for participation.

Keywords: macular degeneration visual impairment implantable telescope
one-stage maxillary sinus elevation using a bone core containing an implant from the mandibular symphysis

Conditions: Atrophied Posterior Maxilla

Summary: two groups of patients with atrophy in posterior maxilla indicated for sinus lift. first group will be subjected to open sinus lift with chin bone graft. second group will be subjected to sinus floor elevation using a bone ring.

two groups of patients with atrophy in posterior maxilla indicated for sinus lift. (a) first group will be subjected to open sinus lift with chin bone graft. * all cases will undergo surgery under general anesthesia for sinus lift and other surgery under local anesthesia for implant placement . * exposure of the anterior wall of maxilla according to standardized surgical approach. * open sinus lift and bone graft. * after 6 months, implant will be drilled and inserted in the recipient site according to standard protocol. * loading on implant after 5-6 months. (b)second group will be subjected to sinus floor elevation using a bone ring. * all cases will undergo surgery under local anesthesia for implant placement in the mandibular chin and other surgery under general anesthesia for sinus lift using bone ring with the implant. * exposure of the mandibular chin will be done under local anesthesia using a standardized surgical approach. * implant will be drilled and inserted in the chin according to standard protocol. * after 3 months, second surgery under general anesthesia to place the implant and surrounding ring in the atrophied posterior maxilla. * the bone ring containing the implant allowed to heal for 5-6 months. follow up: * clinical evaluation will be performed at the first week post-operative. * three months post-operative second surgery to put the implant with surrounding ring in atrophied posterior maxilla. * five months post-operative to the second surgery, implant will be loaded with the final restoration.

Eligibility criteria:
inclusion criteria: 1. patients with at least a unilateral atrophied posterior maxilla indicated for open sinus lift and graft. 2. all ages and both sexes were included in this study. 3. patients should be free from any systemic disease that may affect normal healing of bone, and predictable outcome. 4. patients with good general condition allowing surgical procedure under general anesthesia. 5. patients with physical and psychological tolerance. exclusion criteria: 1. patients with high risk systemic diseases like uncontrolled diabetes. as uncontrolled diabetes has a negative impact on normal bone healing. 2. patients with chronic sinusitis, maxillary sinus tumor or cyst. as they will affect accuracy of the procedure. 3. patients with physical and psychological intolerance. as psychological stress will affect the immune system and patient's fitness including healing capacity. \]

Keywords: implant, bone ring, sinus lift.